The deal priced below last closing price of $4.51. ThinkEquity is acting as sole book running manager for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVM:
- CEL-SCI announces common stock offering, no amount given
- CEL-SCI completes Breakthrough Medicine Designation application for Multikine
- CEL-SCI expects 1 for 30 combination of common stock to be implemented on May 20
- CEL-SCI says publication supports strategy to seek early approval for multikine
- CEL-SCI publishes new data from Multikine study